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Abstract: Many of the links between diet and cancer are controversial and over simplified. To date,
human epidemiological studies consistently reveal that patients who suffer diet-related obesity
and/or type II diabetes have an increased risk of cancer, suffer more aggressive cancers, and respond
poorly to current therapies. However, the underlying molecular mechanisms that increase cancer
risk and decrease the response to cancer therapies in these patients remain largely unknown. Here,
we review studies in mouse cancer models in which either dietary or genetic manipulation has been
used to model obesity and/or type II diabetes. These studies demonstrate an emerging role for the
conserved insulin and insulin-like growth factor signaling pathways as links between diet and cancer
progression. However, these models are time consuming to develop and expensive to maintain.
As the world faces an epidemic of obesity and type II diabetes we argue that the development of novel
animal models is urgently required. We make the case for Drosophila as providing an unparalleled
opportunity to combine dietary manipulation with models of human metabolic disease and cancer.
Thus, combining diet and cancer models in Drosophila can rapidly and significantly advance our
understanding of the conserved molecular mechanisms that link diet and diet-related metabolic
disorders to poor cancer patient prognosis.
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1. Introduction
The effect of nutrition on cancer has received much attention, spawning an industry of books
and websites purporting a vast array of controversial dietary information and supplements for cancer
patients. A plethora of ‘recommended’ diets exist, ranging from those that claim to prevent cancer to
those suggesting food types and supplements that enhance the effectiveness of therapy and prevent
relapse [1,2]. Often dietary guidelines are contradictory and subject to change, promoting anxiety in
the general public, cancer patients and their carers [3]. Overall, although identification of the precise
dietary components that influence cancer biology is controversial, one clear finding has emerged:
individuals with diet-related metabolic disorders, such as obesity and type II diabetes, have an
increased cancer risk. In addition their cancers are more aggressive and more resistant to current
therapies, compounding the prognosis of these patients [4–8].
The earliest suggestion of a link between diet and cancer arose from laboratory mouse studies
conducted in the 1940s [9]. These early reports demonstrated that underfeeding, by restricting dietary
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intake of calories by approximately one third, caused a significant reduction in tumor incidence and
tumor growth in mice. This led to the suggestion that perhaps all cancers respond to dietary influence.
The first compelling human epidemiological studies to reveal a causal relationship between diet and
cancer noted changes in cancer incidence in migrant populations. Notably, Japanese women have
a ten-times lower incidence of breast cancer than do residents of Western countries, but when these
women migrated to Hawaii, their incidence of breast cancer rose to a similar level as found in the
Caucasian Hawaiian population [10]. Later studies highlighted variability in rates of specific cancers
between different countries and gave rise to the concept of the healthy ‘Mediterranean diet’ [11]
amongst others.
There have since been numerous epidemiological studies assessing the effect of various specific
dietary factors on the incidence of cancer [12]. Taken together, these suggest that alcohol, fat, and red
meats are associated with increased risk of colorectal, liver, and breast cancers, whilst a range of fruit
and vegetables including red grapes, garlic, and turmeric offer protective effects [12–15]. Many of the
early studies focused on a single dietary component, such as resveratrol, which is found in red grapes,
peanuts, and berries. These studies revealed conflicting and/or inconclusive findings [15].
Nevertheless, in the last decade one clear theme has emerged: obesity and obesity-related diseases,
in particular type II diabetes, are associated with increased risk of colon, uterine, liver, pancreatic, breast
(in post-menopausal women), and prostate cancers amongst others [16]. In 2012, estimates claimed that
obesity contributed to an additional 3.6% (or 481,000) of all new cancer cases worldwide (excluding
melanoma), with the greatest burden on Europe, North America, and Australia [17]. In breast cancer,
excess weight and obesity also drive cancer progression, and are associated with recurrence [18,19],
metastasis to bone and poor response to chemotherapeutic agents [20]. Whilst an association between
obesity/type II diabetes and sub-types of prostate cancer is unresolved [21,22], there is strong evidence
for a relationship between obesity and an elevated risk of aggressive prostate cancer [23]. Cancers
of the breast and prostate are some of the most commonly diagnosed, and are the leading causes of
cancer death in women and men, respectively. Moreover, the largest cohorts of cancer survivors are
those treated for breast and prostate cancer, yet those who additionally suffer obesity have increased
chance of relapse and respond poorly to further cancer therapies [19].
Despite the potential impact of diet on cancer, and its associated economic burden, the mechanistic
links between diet, dietary related metabolic disorders, and cancer remain poorly understood. Such
mechanistic studies cannot be conducted using in vitro tissue-engineered tumor models because
these fail to mimic the interactions between tumor cells, organ systems and diet that occur in whole
animals. Thus, a significant barrier to current cancer research is the need to use whole animal models.
Transgenic mouse models that manipulate nutrient status and cancer are in their infancy [24] and
complex mouse models genetically targeting metabolic and cancer pathways are both technically
challenging to develop and expensive to maintain [25]. The ability to readily manipulate the Drosophila
melanogaster genome in order to alter gene function, either throughout the whole animal or within
specific cell types, allows the molecular mechanisms of gene function to be characterized at a level of
resolution not possible in current vertebrate models. Additionally, the low cost and rapid generation
of multiple genetic and cell biology tools in Drosophila results in efficient in vivo investigation of
the metabolic and growth pathways that underlie tumorigenesis. The conservation of fundamental
biology and physiology between flies and humans, has allowed Drosophila researchers to deliver
pivotal breakthroughs in our understanding of tumor biology [26–28]. Therefore, innovative models
using a simpler animal system, the vinegar fly Drosophila melanogaster, may increase our capacity to
make a timely and relevant contribution to understanding the relationships between cancer, diet, and
dietary-induced metabolic disorders.
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2. Modeling Interactions between Diet and Cancer in Mice
2.1. Modeling Cancer in Mice
To gain knowledge of the links between diet and cancer, animal models in which the aetiology of
human cancers can be recapitulated whilst altering dietary inputs and monitoring metabolic and tumor
biology are required. The laboratory mouse has a long history of providing fundamental insights
into the mechanisms of cancer initiation, progression and metastasis [29]. Two major tools for cancer
studies in mice are xenografts and genetically-engineered mouse models (GEMM), both of which have
advantages and disadvantages for studying human cancers.
The current gold standard of xenograft models is the ‘human-in-mouse’ xenografts (i.e.,
patient-derived xenografts) in which advanced tumor fragments or metastases are implanted into
an immunodeficient mouse subcutaneously, or, with greater difficulty, orthotopically (i.e., into the
organ of interest). The major advantage of this system is that initially tumors retain human-specific
microenvironment features, which are more reflective of the histology, natural architecture and
genetic heterogeneity seen in primary tumors [30]. Unfortunately, a major obstacle to patient-derived
xenograft modeling is the extremely poor engraftment rate of common tumor types, such as estrogen
receptor-positive breast and prostate cancers [31]. In addition, and importantly, patient-derived
xenografts may not completely recapitulate tumor heterogeneity as the cells that grow may only
represent a subpopulation of tumor cells. Another limitation of xenograft cancer models is that tumor
growth occurs in a host with an impaired immune system, thereby bypassing the anti- and pro-tumor
activity of the adaptive immune system. Thus, although the patient-derived xenograft cancer models
are essential tools for in vivo assessment of cancer biology, their utility for modeling diet and cancer
interaction is limited.
Genetically-engineered mouse models circumvent several issues that arise using patient-derived
xenograft models because tumors arise in situ where inflammatory processes can interact with the
developing tumor. Ideal GEMMs of human cancers feature tumors that carry the corresponding
human mutation and that arise in a small subset of cells within normal tissue, where the steps in cancer
progression (e.g., acquisition of secondary mutations, changes in tumor cell metabolism and ability
to metastasize) closely resemble human pathologies [32]. However, a major limitation of GEMMs is
that development and validation of these models is time-consuming, laborious, and expensive. This is
exemplified when a novel mutation is introduced in an existing multi-allelic mouse model, as this
requires extensive breeding. Several strategies have been devised to overcome some of these problems.
For example, multiple transgenic constructs, knockouts or knockins can be introduced into embryonic
stem (ES) cells that are then used to generate experimental animals [33]. An advantage of this approach
is that modified ES cells carrying multiple genetic manipulations can be frozen and stored until needed,
greatly reducing the costs associated with maintaining complex mouse strains. Inhalation of viral
vectors bearing one or more cDNAs or shRNAs directly in vivo into the adult mouse lung has also
proven to be an effective strategy to test the role of multiple genetic changes in tumorigenesis [34].
However, it remains to be determined if viral delivery of genetic material into other adult mouse
organs will be as fruitful.
2.2. Investigating Interactions between Diet and Cancer in Mice
Despite the substantial human epidemiological evidence that reveals a clear association between
cancer and diet, this area of human health is noticeably understudied. Yet, even with such limited study,
increased tumor growth, and more aggressive metastatic disease has been observed in animals reared
on high calorie diets for a variety of mouse cancer models, including pancreatic [35], prostate [36,37],
ovarian [38], and breast cancers [39].
The most well-studied models combining cancer and diet manipulation are colorectal cancer
models using xenografts or GEMMs [24,40]. For example, human colon cancer HT-29 cells xenografted
under the skin of mice generate tumors that metastasize, accompanied by changes in cell shape
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and migratory behavior (epithelial to mesenchymal transition (EMT)). When animals bearing HT-29
xenografts were fed a high fat diet this resulted in tumor growth associated with increased activation
of the mitogen-activated protein kinase (MAPK) and Phosphatidylinositol 3-kinase (PI3K) pathways,
and tumor cells showed accelerated EMT progression [41]. Additionally, as discussed above, this
xenograft model is ectopic and was performed in immunodeficient mice. This means that the impact
of the known chronic state of site-specific low-grade inflammation that occurs in humans due to the
consumption of a high fat diet, which is hypothesised to promote tumor development and growth [42],
cannot be examined. Thus, it can be more revealing to combine dietary manipulation with GEMMs of
cancer to truly understand the complex interactions between diet and cancer biology. In this regard,
the discovery of a mutant mouse with multiple intestinal neoplasia (Min) has led to the development
of several excellent mouse models to study the early stages of human colon cancer and the effects of
dietary manipulation on cancer progression. Min mice have a mutation that results in truncation of the
adenomatous polyposis coli (Apc) protein, similar to that found in patients with familial adenomatous
polyposis and in 80% of patients with sporadic colon cancers [43]. Heterozygous ApcMin/+ mice fed an
‘obesogenic American-diet’ showed increased polyp size, but no change in total polyp number [44].
This report also demonstrated that the ‘American-diet’ altered immune cell behavior in adipose tissue
and the tumor microenvironment [44], providing an excellent model system to further explore the
systemic impacts of obesity upon tumorigenesis. Conversely, ApcMin/+ mice have also been used to
demonstrate that introducing a source of high dietary fiber (rice bran) decreased tumor burden [45].
These studies also identified changes in metabolic pathways and a weak correlation between increased
levels of the hormone adiponectin (involved in regulating glucose levels and fatty acid breakdown),
and decreased polyp number. Thus, providing new insight into pathways that maybe beneficial for
cancer diagnosis or treatment. However, the cellular and molecular relationship between adiponectin
levels and tumor biology is still unknown. Thus, establishment of mouse cancer models that display
altered cancer progression in response to dietary inputs now provides researchers with the ability to
identify the molecular interactions between diet and cancer which impact tumor growth.
It is clear that mouse models can provide invaluable insights into the relationship between diet and
cancer progression. However one problem with these studies is the lack of detail provided to describe
the diets used in different laboratories. Currently, there are a number of high fat or high sugar diets
commercially available such as the ‘Western’, ‘Sweet Stuff’, or ‘Strictly Vegan’ diets from the Jackson
Laboratories (Bar Harbor, CA, USA), or the high and low fat diets from BioServ Inc. (Frenchtown,
NJ, USA) and Research Diets (New Brunswick, NJ, USA). Furthermore, several research groups use
‘in house’ designer diets such as the ‘American-diet’ [44]. Careful documentation of dietary regimes
including specific amounts of macronutrients (such as protein and carbohydrate) and micronutrients
(such as vitamins and minerals) together with feeding regimes, is needed to allow meta analyses to
assess the roles of different nutrients on tumor progression. These analyses will also shed light on
whether calories derived from fats, sugars or proteins impact tumor growth equally. Furthermore,
incorporating the genetic background of mice into meta-analyses will enable the interactions between
cancer, diet, and genes to be examined. Finally, for mouse cancer models to be of maximum benefit to
human health, mouse models designed to capture the complexities of diet-related human diseases
coupled with dietary intervention trials must also be developed.
3. Investigating Interactions between Cancer, Type II Diabetes Mellitus, and Obesity in Mice
Although the mechanisms that underlie increased susceptibility to cancer in individuals with
type II diabetes or obesity remain largely unknown, several concepts are beginning to emerge through
the study of mouse models that combine cancer with a model of obesity/ type II diabetes (generated
by a genetically engineered deletion of the Insulin Growth factor 1 (IGF1)) [46,47]. For example,
tumor progression from xenografts taken from a variety of mouse transgenic breast cancer strains
(mouse mammary tumor virus (MMTV) -Neu, c-Myc or vascular endothelial growth factor (VEGF))
is accelerated in IGF1 deficient mice [46,48]. Cancers in these animals displayed a number of known
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essential mechanisms for tumor cell proliferation, survival, and metastasis. These include sufficiently
elevated insulin levels to promote InR signaling, increased levels of the powerful oncogene c-Myc,
increased angiogenesis via VEGF, and elevated levels of the extra cellular matrix degradation protein
matrix metalloprotease-9 [49,50]. Further studies of cancer progression in mice deficient for IGF1
suggest that these mechanisms of tumor growth may be applicable to colon [51] and pancreatic [52,53]
cancers. Taken together, mice with a genetically engineered IGF1 deletion have increased the capacity
of researchers not only to understand how type II diabetes contributes to tumor growth, but also how
this complex multifactorial disease impacts the tumor microenvironment and promotes metastasis.
Recent studies have begun to shed light on the potential molecular mechanisms that may link
obesity with aggressive cancer progression and poor outcomes in breast cancer patients [54]. Emerging
evidence suggests elevated levels of circulating adipose fatty acid binding protein (A-FABP) in obese
patients correlates with elevated alcohol dehydrogenase 1 (ALDH1) levels in breast tumor cells
and also with poor prognosis in obese breast cancer patients [54–56]. Injection of in vitro cultured
breast tumor cells under the mammary fat pad of wildtype mice resulted in the release of A-FABP
from adipose tissues and a concomitant increase in the expression of ALDH1 in transplanted tumor
cells. Importantly, in GEMM that lacked A-FABP, ALDH1 expression levels and tumor growth were
reduced in transplanted breast tumor cells. Furthermore, A-FABP-/- mutant mice bearing orthotopically
injected breast cancer cells fed a high fat diet show reduced tumor burden compared to A-FABP-/-
mice on a low fat diet. Finally, in a GEMM of post-menopausal breast cancer (MMTV-Transforming
Growth Factor) loss of A-FABP also showed reduced ALDH1 positive cells and decreased tumor
growth [54]. These results suggest that circulating A-FABP enhances the aggressiveness of mammary
tumor cells in both transplantation and transgenic mouse models. A-FABP activates the Interleukin
6/Signal Transducer and Activator of Transcription 3/ALDH1 pathway within breast tumor cells
which promotes a stem cell phenotype that enhances the aggressiveness of these tumor cells [54]. Thus,
A-FABP may represent a new link between obesity and increased risk of breast cancer and provide
new diagnostic or therapeutic opportunities for patients.
4. Using Drosophila to Model Interactions between Diet, Diet-Related Disease, and Cancer
Despite progress using mice to model diet, obesity-type II diabetes, and cancer interactions,
significant issues remain with these models. Predominantly, mouse models that manipulate nutrient
status are in their infancy, and complex mouse models targeting multiple cancer pathways are
technically challenging and expensive to maintain. We argue that the vinegar fly Drosophila melanogaster
is an excellent model for addressing fundamental aspects of the interaction between diet and cancer.
They are inexpensive to maintain, small, and have a simple diet, and therefore a vast number can
be kept in the laboratory. Their short lifecycle (9–10 days) and exemption from many regulatory
considerations ensures rapid and timely progress can be made, particularly with respect to cancer
studies that can take several months or years to complete in mice. In addition, Drosophila researchers
have developed powerful genetic techniques and dietary models that allow for the rapid identification
and characterization of genes involved in multiple human diseases, which include cancer and
metabolic disorders [57,58]. In particular, Drosophila offers unparalleled opportunities for genetically
manipulating multiple genes and pathways in a tissue-specific manner (needed for cancer studies)
within a whole animal model (needed for dietary studies). Second, the similarity of cellular processes
such as growth and metabolism and the emerging evidence of functional conservation of genes between
Drosophila and mammals mean that studies in flies can directly contribute to the understanding of
human disease [59,60].
Notwithstanding the advantages of using Drosophila to investigate human cancers and metabolic
disorders, there are also several limitations that should be considered. First, a clear physiological
difference between flies and mammals is the optimal body temperature. Flies are ectotherms and can
be successfully reared between 18 and 27 ◦C whilst humans are endothermic and closely maintain a
body temperature of approximately 37 ◦C. As ectoderms do not have to maintain body temperature
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it has been proposed that these animals expend more energy on growth and reproduction than
endoderms [61]. Hence, the relationship between diet, energy expenditure, and animal growth
between flies and humans may be biased towards different physiological outcomes. Second, flies lack
a clear equivalent of breast, prostrate, and lung tissues, thus preventing directly comparable models
of these cancers from being generated. Nevertheless, human epithelial and stem cell cancers have
been successfully modeled in Drosophila [26]. Drosophila also lack a closed circulatory system rendering
the modeling of tumor induced angiogenesis and associated changes in the tumor microenvironment
difficult. Finally, Drosophila models of drug discovery may be limited due to differences in drug
metabolism pathways between flies and humans [60,62].
4.1. Modeling Diet-Related Human Metabolic Diseases in Drosophila
Although humans and flies differ greatly in terms of their gross morphology, many of the digestive
and endocrine systems that control nutrient uptake, storage, and metabolism in humans are also present
in Drosophila [63,64]. Food is digested and absorbed in the fly proventriculus and midgut as in the
mammalian stomach and intestine [65]. Key organs that regulate major metabolic pathways and energy
storage, such as the liver and pancreas in mammals, are also conserved in the larva and adult fly as
oenocytes, fat bodies, and neuronal insulin producing cells (iPCs) respectively [66,67] (Figure 1).
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Figure 1. Schematic representation of conserved human and Drosophilametabolic organs. Metabolism in
Drosophila is coordinated by a network of organs that perform the same basic cellular and physiological
functions as in humans. (A) Frontal view of the major metabolic organs liver, gut and pancreas in
humans. (B) Dorsolateral view of a Drosophila larva with conserved metabolic tissues highlighted.
The blue fat body and oenocyte cells perform similar functions to the human liver, w ilst the ring gland
and insulin p oducing cells within the larval brain secrete glucagon, insulin and ins lin-like peptides
respectively to maintain glucos homeostasis.
In mam als, glucagon and insulin sec t reatic α and β cells respectively, maintain
blood sugar levels. In Drosophila, endocri t anterior to the brain secr te Adipokinetic
hormone (AKH) tha is equivalent to gluca on, whilst iPCs located within the fly brain are analogous
to pancreatic cells (Figure 1).
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In flies, the fat body takes on the dual role of liver and adipose tissue, storing energy in the form of
both glycogen and lipids and releasing energy in the form of the glucose disaccharide trehaolse. Similar
to the liver, the fat body also serves as an endocrine organ, secreting peptides such as insulin-like
peptide 6 (iLP6) to coordinate metabolic homeostasis [68]. One target of secreted iLP6 is the oenocytes
which have a critical role in fat mobilization and turnover in starved larvae. Oenocytes accumulate lipid
droplets during starvation to release ketones and express many genes with homology to liver-specific
enzymes in mammals. These traits have led to the concept that oenocytes are equivalent to liver
hepatocytes [23,69,70].
The biochemical pathways responsible for regulating appropriate circulating sugar levels and
energy storage in mammals are also highly conserved in Drosophila [71,72]. Conserved regulators of
nutrient transport [73], cellular sugar and amino acid flux [74], mitochondrial energy pathways [75], the
hormones insulin and glucagon, and signaling pathways such as Insulin Receptor-mammalian Target
Of Rapamycin (InR-mTOR) share sequence, structural, and functional similarities with vertebrate
homologues [76]. In mammals, IGFs regulate growth via Insulin Growth Factor Receptors, whereas
insulin maintains glucose homeostasis via the InR. However, in flies the single InR regulates both
metabolism and animal growth [77]. Thus, Drosophila models can be used to investigate various aspects
of vertebrate metabolic function including diet, nutrient uptake and the regulation of energy storage
or expenditure.
Importantly, Drosophila larvae reared on a high sugar diet (HSD, 34% sucrose) or a high fat diet
(HFD, 20% coconut oil) exhibit hallmarks of human type II diabetes [78,79]. These animals display high
circulating trehalose levels (hyperglycemia), with increased insulin like peptide 2 (iLP2) mRNA, and
protein expression, and elevated circulating iLP2 levels. Importantly, larvae raised on a HSD or HFD
supplemented with insulin show reduced responses to insulin and diminished activation of the InR
pathway target Protein Kinase B (Akt), indicating Drosophila larvae raised on a HSD or HFD display
insulin resistance, which is a defining feature of type II diabetes. Finally, insulin resistant diabetes is
often present in obese patients, and larvae raised on a HSD and HFD accumulate stored fat in the form
of triacylglycerides and free fatty acids [78–80]. Thus, it appears that the links between diet, obesity and
type II diabetes are evolutionarily conserved, suggesting that Drosophila is an excellent model to explore
the genetic and molecular mechanisms that link dietary fats and sugars to human diseases [81].
4.2. Investigating Interactions between Diet and Cancer in Drosophila
Since the identification of the first tumor suppressor mutations in Drosophila [82], flies have
provided pivotal breakthroughs in our understanding of cancer biology. These seminal contributions
are highlighted in recent reviews [26,28], therefore we focus here on how Drosophila studies are shedding
light on the relationship between cancer and diet. In flies, it is possible to generate groups of tumor
cells in patches of epithelial tissue surrounded by a normal cellular and signaling environment, thus
mimicking the sporadic nature of human tumorigenesis [83]. Furthermore, hemocytes (invertebrate
innate immune cells) are recruited to tumors, modeling anti- and pro- tumor interactions with the
adaptive immune system [84]. In one study that investigated the impact of diet, the proliferation
of cells bearing a loss of function mutation in the tumor suppressor gene Phosphatase and tensin
homolog (PTEN, a negative regulator of PI3K signaling) was shown to be increased under conditions
of nutrient restriction (e.g., caloric restriction of protein by 45% and sugar by 25%) [85]. Thus, PTEN
mutant cells increase tumor growth via cell multiplication under conditions of amino acid starvation
and energy stress. The increased proliferation of PTEN mutant cells facing severe nutrient restriction
comes at the expense of neighboring wildtype cells. PTEN mutant tissue is metabolically more active
and outcompetes the surrounding wildtype tissue for nutrients via the InR pathway. In addition, under
conditions of nutrient restriction PTEN mutant cells also sustain their energy needs by systemically
reducing the growth of organs throughout the entire animal [85]. The mechanisms behind the reduction
in organ growth are as yet unknown. These studies clearly demonstrate that diet-cancer cell interactions
can influence the survival of neighboring normal tissue and organ growth throughout the entire animal.
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4.3. Investigating Interactions between Dietary Related Metabolic Disorders and Cancer in Drosophila
The laboratory of Ross Cagan was the first to establish a Drosophila sugar-enhanced cancer
model (SECM) [86]. This model capitalizes on the powerful molecular genetic approaches possible
in Drosophila to model human tumor development, and the ability of a high sugar diet (HSD) to
induce type II diabetes in growing larvae. Drosophila SECM tumor cells contain the cskQ156STOP
mutation that results in activation of the potent oncogene Src. In addition, these tumor cells also
overexpress an activated isoform of the small GTPase Ras (RasV12). This mimics the elevated Src and
Ras signaling observed in a number of human cancers including breast, colorectal and pancreatic
cancers [87]. In larvae raised on a low sugar diet (10% sucrose), RasV12/Src co-activated cells develop
small, slow-growing tumors within the epithelial tissue. By contrast, in larvae raised on a HSD the
RasV12/Src co-activated cells develop large primary tumors, as well as metastatic secondary tumors
due to increased Wingless (Wnt in mammals) signaling [86]. Thus, raising tumor-bearing larvae on a
HSD leads to increased tumor growth and metastatic spread.
A major advantage of the Drosophila SECM is the ease with which secondary mutations that alter
tumor growth can be then introduced into these flies, enabling mechanistic studies of links between
diet and cancer signaling pathways to be performed. For example, the Cagan lab showed that members
of the conserved AMP activated kinase family, Drosophila Salt Inducible Kinases 2 and 3 (SIK2 and 3),
were required for tumor growth specifically on a high sugar diet [88]. These studies showed that SIKs
regulated tumor growth via the conserved Hippo signaling pathway. However, the role of SIKs in
tumor cell metabolism was not examined, which is important to do because in both flies and mammals
SIKs are well characterized as critical regulators of cell metabolism, specifically lipid and glucose
homeostasis [89–93].
Studies in Drosophila show that SIK3 improves animal survival when exposed to increased dietary
sugar levels [94]. SIK3 directly phosphorylates and activates glucose-6-phosphate dehydrogenase to
promote catabolism of glucose via the pentose phosphate pathway (PPP) [94]. The PPP is an important
source of reducing power in the form of NADPH, which is thought to alleviate sugar-induced oxidative
stress by maintaining capacity to reduce the cellular antioxidant glutathione [94]. In contrast to normal
cells, which primarily rely upon mitochondrial oxidative phosphorylation to generate energy, most
tumor cells rely on anaerobic glucose catabolism (the Warburg effect) [95,96]. We do not know what the
metabolic role of SIKs in tumor cells undergoing anaerobic glucose catabolism is, nor do we know if
high sugar levels impact the activity of the SIKs in tumor cells. This is of interest because human SIKs
(hSIKs1-3) were recently discovered to be oncogenes and are attractive candidates for the treatment
and diagnosis of cancer [97].
In ovarian cancers, 85% of tumor samples show elevated hSIK3 levels [98]. In addition,
overexpression of hSIK2 or hSIK3 in human ovarian and breast cell lines demonstrated that hSIKs
promote cell proliferation, whilst knockdown of hSIK2 or hSIK3 revealed these kinases are required
for tumor cell proliferation [98–100]. Further studies demonstrated that, within cells of the tumor
microenvironment, increased hSIK2 or hSIK3 activity induces changes in fatty acid and arginine
metabolism, which promoted metastasis and growth of secondary tumors [100,101]. These findings
highlight that SIKs can orchestrate both metabolic and growth pathways in tumor cells to promote
cell survival, proliferation and metastasis. Thus, the conserved SIKs provide a unique and exciting
entry point for the dissection of the molecular mechanisms that coordinate diet, cell metabolism and
tissue growth. Studying SIKs in Drosophila and mouse cancer models that also recapitulate diet, obesity
and/or type II diabetes interactions will be crucial to identify growth signaling and/or metabolic
pathways that may provide new avenues for cancer diagnostics and therapies.
4.4. Development of Dietary Regimes in Drosophila to Study Interactions between Diet and Cancer
Much of the cancer-related dietary research in both Drosophila and mice has traditionally focused
on caloric restriction, where energy intake is reduced by decreasing the amount of food (diluting food)
to around 10–50% or increased by over-nutrition. However, diet is complex and there is debate as to
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whether the effects of caloric restriction and over-nutrition are due to altered calories or altered intake
of specific macronutrient proportions; primarily protein, fat and sugar [102,103]. There is growing
evidence from studies on a wide range of species that, rather than sugar, fat or protein acting alone,
it is the balance between macronutrients that is more important for health. In particular, in flies and
mice it has emerged that the balance of protein to carbohydrate in the diet is especially significant,
influencing total energy intake, growth and development, reproduction, and aging [104–108]. The past
decade has seen the development of a variety of new dietary tools, including nutritional geometry and
the defined diet, to assess Drosophila development and growth [109–112]. Nutritional geometry is of
particular interest, as it implements a systematic approach to reveal the effects of macronutrient (e.g.,
carbohydrate, protein, or fat) interactions with a phenotype of interest. Thus, nutritional geometry is a
useful tool to dissect the relative contributions of genes and diet on cancer development.
Nutritional geometry analyses the integrated effects of nutrients and their relative concentrations
on biological outcomes, rather than considering particular nutrients in isolation. Individual animals are
displayed as separate points in multi-dimensional nutrient space, where the dimensions of that space
are defined by particular nutrients of interest (e.g., protein and carbohydrate). The coordinates
of the point representing an individual are defined by its nutritional history. Any quantitative
phenotype of interest, e.g., animal growth, tumor growth or number of metastases, can be plotted as
a surface in the z-axis (Figure 2). Statistical models can then be used to assess how phenotypes are
affected by individual or interacting effects of the major macronutrients, such as dietary protein and
carbohydrate [111]. These studies have provided key insights into the role of macronutrient balance in
altering animal physiology. To date no studies have been undertaken in Drosophila to monitor tumor
growth or metastasis in flies raised on diets with systematically varying protein and carbohydrate
ratios. Importantly, such studies are now possible in Drosophila given the recent development of
defined synthetic diets that enable complete freedom to manipulate the relative proportion of any
nutrient in the diet [110]. By combining Drosophila cancer models with nutritional geometry studies it
will be possible to generate unique experimental paradigms to further define and interrogate how diet
influences cancer–diet interactions.
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Figure 2. Graphical representation of Nutritional Geometry. A hypothetical interaction between protein
(P) and carbohydrate (C) content within the larval diet on tumor size. Larvae fed a diet of both high
protein and sugars are predicted to display the greatest levels of tumor growth. The response surface
(represented by the colour gradient and thin black contours), generated using thin plate splines, is
generated by fitting to tumor size across the nine different diets (filled black circles). These diets consist
of one of three P:C ratios (dashed black lines; P:C = 1:2, 1:5, or 1:10) at one of three caloric densities
(25%, 50%, and 100%; represented by blue dashed lines). In this case, tumor size is maximised by diets
with a high P:C ratio and low caloric density. Tumor size increases as dietary protein increases, with no
effect of dietary carbohydrates.
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4.5. New Genetic Tools in Drosophila will Further Facilitate Studying Interactions between Diet-Related
Metabolic Disorders and Cancer
The workhorse of Drosophila genetics is the UAS-GAL4 system, which is used to manipulate
gene expression in a tissue and timing-specific manner. This system is based upon the yeast GAL4
transcriptional activator and its DNA target, Upstream Activating Sequence (UAS) [113]. A wide
variety of GAL4 driver lines with defined patterns of expression have been generated by many
researchers. Furthermore, a large number of UAS lines that express Drosophila or human genes,
or induce RNA interference (RNAi) and therefore reduce gene expression, have been described.
These tools underpin multiple experimental approaches that have enabled Drosophila researchers to stay
at the forefront of biological research [114]. Alternative bipartite Q or LexA/LexAop transgene systems
have also been developed in Drosophila [115–118]. Combining more than one of these systems will allow
the generation of animals in which a variety of genetic manipulations occur independently in multiple
tissue types. Thus, we now have the ability to manipulate gene expression separately in distinct organs
such as the Drosophila equivalent of the liver (fat body) or gut. This builds capacity to undertake
systemic approaches in Drosophila cancer models, allowing researchers to shed light on the interplay
between tumor growth, metastasis, and organ systems throughout the body. By taking advantage of
these dual transgene expression systems in Drosophila it will now be possible to generate tumors within
the fly and manipulate the expression of circulating hormones, and metabolic genes and pathways in
specific organs, thereby modeling the complex interactions between cancer progression and metabolic
processes in distant organs. Drosophila researchers are thus poised to generate new insights into
communication between tumor cells and peripheral organs, which is critical for distributing energy
stores and maintaining cancer growth.
5. Conclusions
We are currently faced with an epidemic of patients with obesity and type II diabetes. Crucially,
these individuals face an increased risk of cancer and decreased survival rates. Resolving the
effects of dietary macronutrients on cancer risk and progression remains a fundamental challenge,
with profound implications for human health. Animal models that allow precise manipulation of
dietary input (nutritional geometry), combined with the capacity to assess nutrient levels, genetically
manipulate metabolic and/or growth-signaling networks in specific tissues and/or tumor cells are
needed. Drosophila provides an excellent model system, as the conservation of fundamental physiology,
and metabolic and growth pathways between flies and humans means that studies in Drosophila can
deliver pivotal breakthroughs in our understanding of nutrition and cancer growth pathways that are
applicable to human health.
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